The AHA today urged the Drug Enforcement Administration to explicitly consider drug shortages when setting and adjusting aggregate production quotas, citing concern that the agency’s proposal to reduce 2020 production quotas for five opioid controlled substances would exacerbate shortages of injectable opioid medications. “Beyond the negative impact on patient care, inadequate supplies of these drugs also creates burdensome and potentially dangerous workarounds for health care staff who must use alternative, often suboptimal products,” AHA wrote. Among other actions, AHA continued to recommend that DEA routinely consult with the Food and Drug Administration when establishing and adjusting quotas. “Obtaining [national drug] shortage data from the FDA will help to ensure that the DEA’s annual production quotas are set to provide adequate supplies for the United States’ legitimate needs,” the association said.

Related News Articles

Headline
The American Society for Health Care Engineering July 1 announced 87 health care facilities as winners of the 2025 Energy to Care Sustainability Champions…
Headline
The U.S. District Court for the Middle District of Tennessee June 30 denied a motion for a preliminary injunction by AbbVie in its lawsuit against the state’s…
Headline
A new AHA video highlights how Corewell Health is transforming youth behavioral health care access in rural Michigan through school-based clinics and…
Headline
Overdose deaths in the U.S. fell 26.9% last year to 80,391, according to estimates from the Centers for Disease Control and Prevention. The agency reported…
Perspective
Public
One year ago, a nurse at Children’s Hospital Colorado went above and beyond in a way that a very young patient and her family will never forget. Kayla…
Headline
Achieving operational and survey readiness on day one is an issue that many health care facilities professionals continue to grapple with, according to…